RESEARCH ARTICLE


The Use of Topical Calcineurin Inhibitors in Atopic Dermatitis



Annie Crissinger1, Nicholas V. Nguyen*, 2
1 Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH, USA
2 Department of Dermatology, University of Colorado, Aurora, CO, USA


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 56
Abstract HTML Views: 692
PDF Downloads: 580
Total Views/Downloads: 1328
Unique Statistics:

Full-Text HTML Views: 44
Abstract HTML Views: 472
PDF Downloads: 372
Total Views/Downloads: 888



© Crissinger and Nguyen; et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Dermatology, University of Colorado, 1655 Aurora Ct, Mail Stop F703, ACP Rm 3233, Aurora, CO 80045-0510, USA; E-mail: nicholas.v.nguyen@ucdenver.edu


Abstract

In recent years, two topical calcineurin inhibitors have emerged as effective alternatives to corticosteroids for the treatment of atopic dermatitis. Decisions regarding first line therapy between pimecrolimus and tacrolimus are often based on anecdotal evidence. Herein, we review the current evidence supporting the use of pimecrolimus and tacrolimus in atopic dermatitis as well as key differences in safety, tolerability, and cost between the drugs.

Keywords: Atopic dermatitis, calcineurin inhibitors, pimecrolimus, tacrolimus.